Alba Català

Alba Català

Auto-generated profile, based on publicly available information

Alba Català

Hospital Plató Barcelona Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
CGCristina Galvan
Cristina Galvan
ACA. Català
A. Català
GHG. Carretero Hernández
G. Carretero Hernández
PJPedro Rodriguez Jimenez
Pedro Rodriguez Jimenez
DFD. Fernández‐Nieto
D. Fernández‐Nieto
IGI. García‐Doval
I. García‐Doval
SummaryBackground. The cutaneous manifestations of COVID‐19 disease are poorly characterized.Objectives. To describe the cutaneous manifestations of COVID‐19 di

10 August 2020 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
ACAlba Català
Alba Català
CGCristina Galván‐Casas
Cristina Galván‐Casas
GCGregorio Carretero‐Hernández
Gregorio Carretero‐Hernández
PJPedro Rodriguez Jimenez
Pedro Rodriguez Jimenez
DFDaniel Fernández‐Nieto
Daniel Fernández‐Nieto
IGIgnacio García‐Doval
Ignacio García‐Doval
Background A previous study has defined the maculopapular subtype of manifestations of COVID‐19. Objectives To describe and classify maculopapular eruptions associated with COVI‐19. Methods We carried out a subanalysis of the maculopapular cases found in the previous cross‐sectional study. Using a consensus, we defined 7 clinical patterns. We described patient demographics, the therapy received by the patient and the characteristics of each pattern. Results Consensus lead to the description of 7 major maculopapular patterns: Morbilliform (45.5%), Other maculopapular (20.0%), Purpuric (14.2%), Erythema multiforme‐like (9.7%), Pytiriasis rosea‐like (5.7%), Erythema elevatum diutinum‐like (2.3%) and Perifollicular (2.3%). In most cases, maculopapular eruptions were coincident (61.9%) or subsequent (34.1%) to the onset of other COVID‐19 manifestations. The most frequent were cough (76%), dyspnea (72%), fever (88%), and astenia (62%). Hospital admission due to pneumonia was frequent (61%). Drug intake was frequent (78%). Laboratory alterations associated with maculo‐papular eruptions were high C‐reactive protein, high D‐Dimer, lymphopenia, high ferritin, high LDH, and high IL‐6. Limitations The impossibility to define the cause–effect relationship of each pattern. Conclusion We provide a description of the cutaneous maculopapular manifestations associated with COVID‐19. The cutaneous manifestations of COVID‐19 are wide‐ranging and can mimic other dermatoses.

1 July 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
ACA. Català
A. Català
CGCristina Galvan
Cristina Galvan
GHG. Carretero Hernández
G. Carretero Hernández
IGI. García‐Doval
I. García‐Doval
We and agree with Drs Lim and Tey on the need to exclude varicella in vesicular eruptions in patients with COVID‐19, as this diagnosis has important implications. Once that it is established that some patients with COVID‐19 can have a vesicular eruption, there is a need to further characterize this group of patients. The link of some of these lesions with herpesvirus infections is very likely. One patient was excluded from our study with a diagnosis of varicella or disseminated herpes zoster.